This study used a multicenter cohort in Italy to identify prognostic indicators for 3-year survival in patients who had undergone extrapleural pneumonectomy (EPP) for mesothelioma. 23% lived 3 years or longer. This survival was related to age, epitheliod histology, lack of asbestos exposure, and involved LN ratio. A risk score for survival was dev
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Cancer
September 4, 2015
August 26, 2015
Investigators from Stanford developed a nine-gene expression predictor for survival outcome in early-stage nonsquamous NSCLC. They developed and validated a quantitative real-time polymerase chain reaction assay easily applicable to routinely obtained paraffin-embedded tumor specimens.
August 22, 2015
This comprehensive review outlines changes in the WHO classification of lung tumors, chagnes that will affect our clinical practice in the near future.
August 20, 2015
Thus far, only 3 randomized controlled trials (RCTs) have compared stereotactive ablative radiotherapy (SABR) versus surgery in patients with early stage NSCLC (STARS trial, ROSEL trial, and ACOSOG Z4099 trial). Unfortunately all 3 were unable to meet the accrual goals and were closed early.
August 20, 2015
This is an invited commentary on the article by Chang and colleagues (Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials).
August 20, 2015
This expert opinion editorial is published in JTCVS in response to the article by Chang and colleagues. Meyers and colleagues begin by emphasizing that a large randomized controlled trial (RCT) would be the best way to answer the question of whether SABR or lobectomy is superior treatment for patients with early stage NSCLC.
August 20, 2015
This is a letter in response to the article by Chang and colleagues. The authors point out that only 58 patients were enrolled from 38 centers over 66.3 months, and speculate that this might be due to patients' preference for surgery.
August 20, 2015
This is a letter in response to the article by Chang and colleagues.
August 20, 2015
This is a letter in response to the article by Chang and colleagues. The authors warn to interpret the findings of the original article, that SABR is better tolerated and might lead to improved survival compared to surgery for good risk patients with clinical stage I NSCLC, with caution. They highlight two pitfalls of the original study.
August 20, 2015
This is a letter in response to the article by Chang and colleagues. The authors begin by stating that the data from this study should be graded according to an internationally accepted system, GRADE.